Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

Olivier Rascol, David J. Brooks, Amos D. Korczyn et al. · New England Journal of Medicine · 2000 · 1.5K citations · Full text

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

Manolo Carta, Thomas Carlsson, Deniz Kirik et al. · Brain · 2007 · 613 citations · Full text

Neurotransmitter, L-dopa-induced Dyskinesia, Spared Serotonin Innervation +18

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

Stephen J. Kish, Junchao Tong, Oleh Hornykiewicz et al. · Brain · 2007 · 377 citations · Full text

Neurotransmitter, Caudate Versus Putamen, Social Sciences +16

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats

Hiroyasu Tanaka, Kazuya Kannari, Tetsuya Maeda et al. · Neuroreport · 1999 · 300 citations

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial

Christopher G. Goetz, Philippe Damier, Christine Hicking et al. · Movement Disorders · 2006 · 252 citations